15 Bradley C. Diabetes treatment satisfaction questionnaire. Change  version for use alongside status version provides appropriate solution where ceiling eﬀ  ects occur. Diabetes Care 1999; 22: 530–32.  16 Heine RJ, Van Gaal LF, Johns D, et al. Exenatide versus insulin  glargine in patients with suboptimally controlled type 2 diabetes:  a randomized trial. Ann Intern M ed   2005; 143: 559–69. 17 Boye KS, Matza LS, Oglesby A, et al. Patient-reported outcomes  in a trial of exenatide and insulin glargine for the treatment of type 2 diabetes. Health Qual Life Outcomes 2006; 4: 80. 18 Barnett AH, Burger J, Johns D, et al. Tolerability and eﬃ   cacy of  exenatide and titrated insulin glargine in adult patients with  type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007; 29: 2333–48. 19 Bergenstal R, Lewin A, Bailey T, Chang D, Gylvin T, Roberts V,